Reassessing Aeva Technologies (AEVA) Valuation After A Very Large One Year Share Price Jump

  • If you are wondering whether Aeva Technologies' current share price lines up with its real value, you are not alone. This article is here to unpack that question step by step.
  • The stock last closed at US$15.16, with returns of 7.0% over 7 days, 19.0% over 30 days, 18.9% year to date, a very large 1 year return that sits well above 400%, a 3 year return of 84.9%, and a 5 year return of a 79.2% decline.
  • These moves have put Aeva back on many watchlists, as investors reassess how the market is pricing its long term prospects and risks. Recent news flow has helped keep attention on the stock, providing context for why sentiment may have shifted, even if the exact drivers of the latest price swings are still being debated.
  • On our checks, Aeva scores 2 out of 6 on valuation, as shown by this value score. We will walk through what different valuation approaches say about that number, then finish with a way to look at valuation that can give you an even clearer view by the end of the article.

Aeva Technologies scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Advertisement

Approach 1: Aeva Technologies Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value in $.

For Aeva Technologies, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $124.2 million. Analyst and extrapolated projections foresee free cash flow remaining negative for several years, then turning positive and reaching an estimated $75.9 million in 2030. These projections include further increases in the years after based on Simply Wall St’s extrapolations.

When those projected cash flows are discounted back, the model points to an estimated intrinsic value of about $61.26 per share, compared with the recent share price of US$15.16. That gap implies the shares are around 75.3% undervalued according to this DCF setup.

This model presents Aeva as a high uncertainty, high potential situation in which the current market price sits well below the DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Aeva Technologies is undervalued by 75.3%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

AEVA Discounted Cash Flow as at Mar 2026
AEVA Discounted Cash Flow as at Mar 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Aeva Technologies.

Approach 2: Aeva Technologies Price vs Book

For companies where profits are limited or volatile, the price to book, or P/B, ratio is often a useful way to think about value, because it compares what you pay in the market with the net assets on the balance sheet.

In general, a higher P/B can be linked to stronger growth expectations or lower perceived risk, while a lower P/B can reflect weaker growth expectations or higher perceived risk. What counts as a “normal” or “fair” P/B depends on the sector, balance sheet quality and how predictable investors think future returns on those assets will be.

Aeva Technologies currently trades on a P/B ratio of 68.92x, compared with an Electronic industry average of 2.36x and a peer group average of 4.53x. Simply Wall St also uses a proprietary “Fair Ratio”, which is the P/B multiple it would expect for Aeva based on factors like its earnings profile, growth outlook, profit margins, market cap, risks and industry.

This Fair Ratio framework can be more informative than simple peer or industry comparisons, because it adjusts for company specific strengths and weaknesses instead of assuming all firms deserve similar multiples. On Simply Wall St’s numbers, Aeva’s actual P/B of 68.92x sits well above its Fair Ratio, which indicates that the shares appear overvalued on this metric.

Result: OVERVALUED

NasdaqGS:AEVA P/B Ratio as at Mar 2026
NasdaqGS:AEVA P/B Ratio as at Mar 2026

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Aeva Technologies Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St you can use Narratives on the Community page, where you set out your story for Aeva Technologies in plain language, tie that story to specific revenue, earnings and margin forecasts, see a Fair Value that comes out of those numbers, and then compare that Fair Value with the current share price to help you decide whether it looks more like a buy, hold or sell for you. The Narrative then updates as new news or earnings arrive and different investor views are visible. For example, one user might align with the more cautious US$18.55 fair value, while another leans toward the higher US$33.00 view based on different expectations for future growth and profitability.

Do you think there's more to the story for Aeva Technologies? Head over to our Community to see what others are saying!

NasdaqGS:AEVA 1-Year Stock Price Chart
NasdaqGS:AEVA 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:AEVA

Aeva Technologies

Engages in the design, manufacture, and sale of LiDAR sensing systems, and related perception and autonomy-enabling software solutions in North America, Europe, Oceania, and Asia.

Moderate risk and slightly overvalued.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
66 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0